Physician

Nuruddin Jooma, M.D.

According to 2025 Medicare claims, Nuruddin Jooma, M.D. (NPI: 1376713727) practices hematology/oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33770-2542.

Jooma's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 858 traditional Medicare patients, billed 331,390 HCPCS/CPT codes, and received $4,796,489 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,812 prescription claims across 405 beneficiaries totaling $7,051,914 in drug costs, led by Revlimid (Lenalidomide). DME data shows 11 claims. Open Payments data shows 141 records totaling $6,755. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $2,496,946 to $7,051,914. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $11,165 and ending at $949.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	957	291,672	$2,797,486
2016	1,137	435,458	$4,415,729
2017	1,375	469,668	$4,545,971
2018	1,408	473,166	$5,096,069
2019	1,445	444,002	$5,527,976
2020	1,314	421,215	$6,229,899
2021	1,143	428,969	$5,692,960
2022	1,045	424,096	$4,953,838
2023	955	461,003	$5,150,993
2024	858	331,390	$4,796,489

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	249	1,398	$2,496,946
2016	302	1,843	$2,550,276
2017	304	1,783	$3,070,560
2018	327	1,556	$2,923,690
2019	335	1,659	$4,276,640
2020	381	1,812	$4,121,802
2021	363	1,618	$3,728,329
2022	391	1,715	$4,496,740
2023	392	1,640	$5,093,538
2024	405	1,812	$7,051,914

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	36	184	$11,364
2016	11	155	$35,691
2017	33	193	$74,394
2018	13	129	$17,966
2019	13	68	$5,721
2020	N/R	61	$4,817
2021	12	77	$5,673
2022	11	34	$3,761
2023	N/R	117	$17,031
2024	N/R	11	$686

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	307	1,012	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	479	872	$66
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	281	395	$13
36415	Insertion of needle into vein for collection of blood sample	602	2,483	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	598	2,588	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	81	2,198	$1,364,335
Tagrisso	Osimertinib Mesylate	53	1,590	$880,307
Cabometyx	Cabozantinib S-Malate	33	990	$713,867
Brukinsa	Zanubrutinib	49	1,470	$533,647
Verzenio	Abemaciclib	34	952	$516,942

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	11	$686

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	141	$6,755	PharmaEssentia USA Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nuruddin Jooma, M.D.?

Tedicare shows public-source Medicare data for Nuruddin Jooma, M.D. (NPI 1376713727), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nuruddin Jooma, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Nuruddin Jooma, M.D.?

Nuruddin Jooma, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Nuruddin Jooma, M.D. have Open Payments data?

Nuruddin Jooma, M.D. has 141 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.